BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
Marius Ueffing	Head of Dept. for Protein Science and Director Institute of Ophthalmology University Medical Center Tübingen
CURRENT AFFILIATION Helmholtz Zentrum München, German Research Center for Environmental Health Department of Protein Science	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Albert Ludwigs Universität Freiburg, Germany		1981-1987	Medicine, Biology
Albert Ludwigs Universität Freiburg, Germany	State Exam	1987	Biology
Columbia University, College of Physicians & Surgeons, New York City, New York, U.S.A.	PhD student Fellow	1988-1991	Tumorgenetics
Albert Ludwigs Universität Freiburg, Germany	PhD	1991	Molecular cell biology
Research Scientist, Goedeke-Parke Davis, Freiburg and New York, USA,		1991-93	Molecular cell biology Pharmaceutical research

List of five recent publications by the candidate:

Meixner, A., Boldt, K., Van Troys, M., Askenazi, M., Gloeckner, C. J., Bauer, M., Marto, J. A., Ampe, C., Kinkl, N. and Ueffing, M. (2010). A QUICK screen for Lrrk2 interaction partners – leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. **Mol Cell Proteomics**; Oct;9(10):2292-305.

Hauck SM, Dietter J, Kramer RL, Hofmaier F, Zipplies JK, Amann B, Feuchtinger A, Deeg CA, Ueffing M. (2010). Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. **Mol Cell Proteomics**. 9:2292-305

Gloeckner CJ, Boldt K, von Zweydorf F, Helm S, Wiesent L, Sarioglu H, Ueffing M. (2010). Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. **J Proteome Res**. 9: 1738-1745.

Hauck SM, Gloeckner JC., Harley ME, Schoeff,man S, Boldt K, Schumacher A., Ekstrom PA. and Ueffing M., (2008). Identification of Paracrine Neuroprotective Candidate Proteins by an Activity-Driven Proteomics Approach, **Mol Cell Proteomics**, Jul;7(7):1349-61

Den Hollander AI, *et al*., Ueffing M, Cremers FP, Inglehearn CF, Roepman R. (2007). Mutations in lebercilin, a novel ciliary protein, cause Leber congenital amaurosis. **Nature Genetics**, Jul; 39(7) 2007:889-95

Gloeckner JC., Boldt K, Schumacher A., Roepman R and Ueffing M (2007). A novel tandem affinity purification strategy for the efficient isolation and characterization of native protein complexes. **Proteomics**, 7; 4228-34.

Please indicate in 200 words or less the reason(s) why you would be a suitable candidate for the HUPO Council elections.

Self-description: As a medical geneticist by training, I have engaged in proteome analysis early on to analyse the impact of human mutations on a systemic level. With a previous background as a group leader in pharmaceutical industry (Goedeke-Parke-Davis) as well as an affiliation with a University Medical Centre (University of Tübingen), I am focused on disease related research. I currently act as the President of the German Society for Proteome Research and Member of the HUPO Board of Directors and participate in several large scale and/or targeted projects on the national and the EU level most importantly „Syscilia“ (http://syscilia.org) and “Affinomics” (www.affinomics.org).

Motivation: Different to the concerted activities in the genome era, where a single ambitious goal to sequence the human genome would bring everybody together, we are now facing a new level of complexity with respect to a proteome centered post-genomic research agenda that requires concerted action and global harmonization of activities. Here, scientific discovery, generation of tools, reagents, methodology and standards, management of knowledge, its integration and dissemination and finally the translation of all that towards generating benefits and value for a better life of people requires proper coordination on a global scale. HUPO can play a leading role and generate critical contributions towards these goals and its mission statement provides a guideline how to achieve them. This motivates me to contribute to it as member of its council. Given my background and previous experience participating in national and international activities, I feel able to contribute especially with respect to my special expertise in generating reagents and toolsets, with my in depth experience in quantitative proteomics and my current activities in systemic analysis of disease.